Latest / Oncology Data Advisor

Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward
In this interview, Dr. Jason Mouabbi, OncData Editorial Board Member and Breast Medical Oncologist at MD Anderson Cancer Center, speaks with Dr. Ross Maclean and Michael Glover about the debate surrounding accelerated FDA approvals, including their benefits, risks, and ways that physicians, patients, pharmaceutical companies, and the FDA can collaborate to maximize the impact of accelerated approval drugs.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.